(MENAFN- PR Newswire)
The BCG unresponsive NMIBC market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of photodynamic therapy and non-viral gene therapy, and raised awareness.
LAS VEGAS, July 3, 2024 /PRNewswire/ -- DelveInsight's
BCG Unresponsive NMIBC Market Insights
report includes a comprehensive understanding of current treatment practices, BCG unresponsive NMIBC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
Key Takeaways from the BCG Unresponsive NMIBC Market Report
According to DelveInsight's analysis, the market size for BCG unresponsive NMIBCs
is expected to grow significantly by 2034.
30% to 50%
of cases involving non-muscle-invasive bladder cancer (NMIBC) do not respond to Bacillus Calmette-Guérin (BCG) treatment.
Leading BCG unresponsive NMIBC
companies such as Johnson & Johnson, enGene , and others are developing novel BCG unresponsive NMIBC drugs that can be available in the BCG unresponsive NMIBC market in the coming years.
The promising
BCG unresponsive NMIBC therapies in the pipeline include TAR-200 (RIS/gemcitabine plus cetrelimab), EG-70, and others.
In
April 2024 , the FDA approved ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ, with or without papillary tumors. ANKTIVA, is first-in-class interleukin-15 agonist immunotherapy for NMIBC.
In
December 2023, Johnson & Johnson announced that the FDA had granted TAR-200 Breakthrough Therapy Designation (BTD) for the potential future treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC), who were ineligible for or elected not to undergo radical cystectomy (surgical removal of the bladder).
Discover which therapies are expected to grab the major BCG unresponsive NMIBC
market share @ BCG Unresponsive NMIBC Market Report
BCG Unresponsive NMIBC Overview
BCG unresponsive non-muscle invasive bladder cancer (NMIBC) is a condition where bladder cancer does not adequately respond to Bacillus Calmette-Guérin (BCG) therapy, a common intravesical treatment for this type of cancer. The causes of BCG unresponsiveness can be multifaceted, including intrinsic resistance of the cancer cells to BCG, inadequate immune response by the patient, or improper administration of the therapy. Symptoms of NMIBC include blood in the urine (hematuria), frequent urination, urgency, and painful urination. As the disease progresses without effective treatment, these symptoms may worsen. Diagnosis involves a combination of methods such as urine cytology, cystoscopy, and biopsy, often supplemented by imaging studies like CT scans or MRIs to assess the extent and grade of the tumor. Identifying BCG unresponsiveness typically requires monitoring tumor recurrence or progression after multiple cycles of BCG therapy, often necessitating a multidisciplinary approach to explore alternative treatments.
BCG Unresponsive NMIBC Epidemiology Segmentation
The BCG unresponsive NMIBC epidemiology section provides insights into the historical and current BCG unresponsive NMIBC patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The BCG unresponsive NMIBC market report
proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
BCG Unresponsive NMIBC Incident Cases
BCG Unresponsive NMIBC Age-specific Cases
BCG Unresponsive NMIBC Gender-specific Cases
BCG Unresponsive NMIBC Risk factor- specific Cases
BCG Unresponsive NMIBC Line-wise Treated Case
BCG Unresponsive NMIBC Treatment Market
BCG-unresponsive non-muscle-invasive bladder cancer poses a significant clinical challenge due to its resistance to standard BCG immunotherapy, which is typically the first-line treatment. This condition arises when patients fail to respond adequately or experience disease recurrence despite undergoing BCG therapy. Managing BCG-unresponsive NMIBC requires careful consideration of alternative treatment options, such as intravesical chemotherapy, immunotherapy with checkpoint inhibitors, or even radical cystectomy in severe cases. The decision-making process involves balancing the risk of disease progression with potential treatment side effects, emphasizing the need for personalized care plans tailored to each patient's specific clinical characteristics and preferences.
Research into novel therapies for BCG-unresponsive NMIBC continues to evolve, aiming to improve outcomes and quality of life for affected individuals. Clinical trials exploring different immunotherapeutic agents targeted therapies, and combination approaches offer hope for more effective treatment strategies. The challenge lies in selecting the most appropriate therapy based on tumor characteristics, patient health status, and previous treatment responses, highlighting the importance of multidisciplinary collaboration among urologists, oncologists, and researchers to advance the field and optimize patient care.
To know more about BCG unresponsive NMIBC treatment guidelines, visit @ BCG Unresponsive NMIBC Management
BCG Unresponsive NMIBC Pipeline Therapies and Key Companies
Some of the drugs in the BCG unresponsive NMIBC pipeline include TAR-200 (RIS/gemcitabine plus cetrelimab) (Johnson & Johnson), EG-70 (enGene) , and others.
TAR-200
is an innovative investigational system designed to provide a sustained local release of gemcitabine into the bladder, ensuring prolonged drug exposure. Cetrelimab, an investigational PD-1 monoclonal antibody, is being studied for the treatment of bladder cancer, prostate cancer, melanoma, and multiple myeloma, and is currently in Phase II trials.
In December 2023, Johnson & Johnson announced that the FDA had granted Breakthrough Therapy Designation (BTD) to TAR-200 for the potential treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) who are either ineligible for or have chosen not to undergo radical cystectomy (bladder removal surgery).
EG-70 (detalimogene voraplasmid)
is an innovative, non-viral gene therapy currently under investigation for treating high-risk, NMIBC with carcinoma in situ (CIS) that does not respond to BCG treatment. EG-70 is designed to activate both the innate and adaptive immune systems within the bladder, aiming to trigger a coordinated immune response to eliminate tumors.
The therapy has shown promising efficacy and safety in patients with BCG-unresponsive, high-risk NMIBC CIS, achieving high complete response rates and demonstrating good tolerability. It is presently being evaluated in Phase I/II clinical trials.
The anticipated launch of these emerging therapies for BCG unresponsive NMIBC
are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the BCG unresponsive NMIBC
market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about BCG unresponsive NMIBC drugs
in development @ BCG Unresponsive NMIBC Clinical Trials
BCG Unresponsive NMIBC Market Dynamics
The market dynamics of BCG unresponsive NMIBC are driven by several critical factors. Firstly, the increasing incidence of bladder cancer globally necessitates effective treatment options for patients who do not respond to or cannot tolerate BCG therapy. Secondly, advancements in diagnostic techniques have improved early detection rates, highlighting the need for alternative therapies when BCG fails. Additionally, regulatory approvals and ongoing clinical trials for novel immunotherapies and targeted agents underscore a growing pipeline of potential treatments, promising new options in a historically challenging therapeutic area.
Furthermore, potential therapies are being investigated for the treatment of BCG unresponsive NMIBC, and it is safe to predict that the treatment space will significantly impact the BCG unresponsive NMIBC
market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the BCG unresponsive NMIBC
market in the 7MM.
However several factors may impede the growth of the BCG unresponsive NMIBC market. Key challenges include the lack of alternative therapies with proven efficacy comparable to BCG, limited understanding of tumor biology leading to inadequate patient stratification, and regulatory complexities in approving novel treatments. Additionally, the high variability in patient responses to existing therapies underscores the urgent need for personalized medicine approaches and innovative clinical trial designs. Addressing these barriers is crucial to improving outcomes and quality of life for patients grappling with BCG-unresponsive NMIBC.
Moreover, BCG unresponsive NMIBC
treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the BCG unresponsive NMIBC
market growth may be offset by failures and discontinuation of emerging therapies , unaffordable pricing , market access and reimbursement issues , and a shortage of healthcare specialists . In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the BCG unresponsive NMIBC
market growth.
| BCG Unresponsive NMIBC Market Report Metrics |
Details |
| Study Period |
2020–2034 |
| Coverage |
7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
| Key BCG Unresponsive NMIBC Companies |
Dompé Farmaceutici S.p.A, Claris Biotherapeutics, Inc. ReGenTree, LLC, and others |
| Key Pipeline BCG Unresponsive NMIBC Therapies |
rhNGF, RGN-259, CSB-001, and others |
Scope of the BCG Unresponsive NMIBC
Market Report
Therapeutic Assessment: BCG Unresponsive NMIBC
current marketed and emerging therapies
BCG Unresponsive NMIBC
Market Dynamics:
Key Market Forecast Assumptions of Emerging BCG Unresponsive NMIBC
Drugs and Market Outlook
Competitive Intelligence Analysis:
SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, BCG Unresponsive NMIBC Market Access and Reimbursement
Download the report to understand which factors are driving BCG unresponsive NMIBC market trends
@
BCG Unresponsive NMIBC Market Trends
Table of Contents
| 1. |
BCG Unresponsive NMIBC Key Insights |
| 2. |
BCG Unresponsive NMIBC Report Introduction |
| 3. |
BCG Unresponsive NMIBC Overview at a Glance |
| 4. |
BCG Unresponsive NMIBC Executive Summary |
| 5 |
BCG Unresponsive NMIBC Key Events |
| 6 |
Epidemiology and Market Forecast Methodology |
| 6. |
Disease Background and Overview |
| 7. |
BCG Unresponsive NMIBC Treatment and Management |
| 8. |
BCG Unresponsive NMIBC Guidelines |
| 9. |
BCG Unresponsive NMIBC Epidemiology and Patient Population |
| 10. |
Patient Journey |
| 11. |
Key Endpoints in BCG Unresponsive NMIBC
|
| 12. |
BCG Unresponsive NMIBC Marketed Drugs |
| 13. |
BCG Unresponsive NMIBC Emerging Drugs |
| 14. |
7MM BCG Unresponsive NMIBC Market Analysis |
| 15. |
Market Access and Reimbursement |
| 16. |
KOL Views |
| 17. |
Unmet Needs |
| 18. |
SWOT Analysis |
| 19. |
Appendix |
| 20. |
DelveInsight Capabilities |
| 21. |
Disclaimer |
| 22. |
About DelveInsight |
Related Reports
Non-Muscle Invasive Bladder Cancer Market
Non-Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast –
2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NMIBC companies including Hoffmann-La Roche, Pfizer, Bristol-Myers Squibb, AstraZeneca, UroGen Pharma, Johnson & Johnson, CG Oncology, ImmunityBio, Theralase Technologies, Protara Therapeutics, enGene, NanOlogy, Asieris Pharmaceutical,
among others.
Non-Muscle Invasive Bladder Cancer
Pipeline
Non-Muscle Invasive Bladder Cancer
Pipeline Insight –
2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-muscle invasive bladder cancer
companies, including UroGen Pharma, CG Oncolgy, Sasanlimab, Sesen Bio, Theralase Technologies, Asieris Pharmaceuticals, Hamlet Pharma, AstraZeneca, Viralytics, ImmunityBio, Prokarium, among others.
Bladder Cancer Market
Bladder Cancer Market Insights, Epidemiology, and Market Forecast –
2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bladder cancer companies including RemeGen Co., Ltd., Taiho Oncology, Inc., Xennials Therapeutics, Flame Biosciences,
among others.
Muscle-Invasive Bladder Cancer Pipeline
Muscle-Invasive Bladder Cancer Pipeline Insight –
2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
muscle-invasive
bladder cancer companies, including SOTIO a.s., Celon Pharma SA, Shanghai PerHum Therapeutics Co., Ltd., 4D Pharma PLC, among others.
About
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform
PharmDelve .
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP
MENAFN03072024003732001241ID1108405049